Ca2+-activated K+ channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model

Pierre Olivier Girodet, Annaig Ozier, Gabrielle Carvalho, Olga Ilina, Olga Ousova, Alain Pierre Gadeau, Hugues Begueret, Heike Wulff, Roger Marthan, Peter Bradding, Patrick Berger

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Key features of asthma include bronchial hyperresponsiveness (BHR), eosinophilic airway inflammation, and bronchial remodeling, characterized by subepithelial collagen deposition, airway fibrosis, and increased bronchial smooth muscle (BSM) mass. The calcium-activated K+ channel K Ca3.1 is expressed by many cells implicated in the pathogenesis of asthma, and is involved in both inflammatory and remodeling responses in a number of tissues. The specific KCa3.1 blocker 5-[(2-chlorophenyl) (diphenyl)methyl]-1H-pyrazole (TRAM-34) attenuates BSM cell proliferation, and both mast cell and fibrocyte recruitment in vitro. We aimed to examine the effects of KCa3.1 blockade on BSM remodeling, airway inflammation, and BHR in a murine model of chronic asthma. BALB/c mice were sensitized with intraperitoneal ovalbumin (OVA) on Days 0 and 14, and then challenged with intranasal OVA during Days 14-75. OVAsensitized/challenged mice received TRAM-34 (120 mg/kg/day, subcutaneous) from Days -7 to 75 (combined treatment), Days -7 to 20 (preventive treatment), or Days 21 to 75 (curative treatment). Untreated mice received daily injections of vehicle (n = 8 per group). Bronchial remodeling was assessed by histological and immunohistochemical analyses. Inflammation was evaluated using bronchoalveolar lavage and flow cytometry. We also determined BHR in both conscious and anesthetized mice via plethysmography. We demonstrated that curative treatment with TRAM-34 abolishes BSM remodeling and subbasement collagen deposition, and attenuates airway eosinophilia. Although curative treatment alone did not significantly reduce BHR, the combined treatment attenuated nonspecific BHR to methacholine. This study indicates that KCa3.1 blockade could provide a new therapeutic strategy in asthma.

Original languageEnglish (US)
Pages (from-to)212-219
Number of pages8
JournalAmerican Journal of Respiratory Cell and Molecular Biology
Volume48
Issue number2
DOIs
StatePublished - Feb 2013

Fingerprint

Airway Remodeling
Calcium-Activated Potassium Channels
Eosinophilia
Muscle
Asthma
Ovalbumin
Collagen
Smooth Muscle
Plethysmography
Flow cytometry
Methacholine Chloride
Inflammation
Cell proliferation
Therapeutics
Tissue
Bronchoalveolar Lavage
TRAM 34
Mast Cells
Smooth Muscle Myocytes
Flow Cytometry

Keywords

  • Asthma
  • Ion channel
  • K3.1
  • Remodeling
  • Smooth muscle

ASJC Scopus subject areas

  • Cell Biology
  • Pulmonary and Respiratory Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Ca2+-activated K+ channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model. / Girodet, Pierre Olivier; Ozier, Annaig; Carvalho, Gabrielle; Ilina, Olga; Ousova, Olga; Gadeau, Alain Pierre; Begueret, Hugues; Wulff, Heike; Marthan, Roger; Bradding, Peter; Berger, Patrick.

In: American Journal of Respiratory Cell and Molecular Biology, Vol. 48, No. 2, 02.2013, p. 212-219.

Research output: Contribution to journalArticle

Girodet, PO, Ozier, A, Carvalho, G, Ilina, O, Ousova, O, Gadeau, AP, Begueret, H, Wulff, H, Marthan, R, Bradding, P & Berger, P 2013, 'Ca2+-activated K+ channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model', American Journal of Respiratory Cell and Molecular Biology, vol. 48, no. 2, pp. 212-219. https://doi.org/10.1165/rcmb.2012-0103OC
Girodet, Pierre Olivier ; Ozier, Annaig ; Carvalho, Gabrielle ; Ilina, Olga ; Ousova, Olga ; Gadeau, Alain Pierre ; Begueret, Hugues ; Wulff, Heike ; Marthan, Roger ; Bradding, Peter ; Berger, Patrick. / Ca2+-activated K+ channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model. In: American Journal of Respiratory Cell and Molecular Biology. 2013 ; Vol. 48, No. 2. pp. 212-219.
@article{1cc7008ebbb8406d91d10b21be7de027,
title = "Ca2+-activated K+ channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model",
abstract = "Key features of asthma include bronchial hyperresponsiveness (BHR), eosinophilic airway inflammation, and bronchial remodeling, characterized by subepithelial collagen deposition, airway fibrosis, and increased bronchial smooth muscle (BSM) mass. The calcium-activated K+ channel K Ca3.1 is expressed by many cells implicated in the pathogenesis of asthma, and is involved in both inflammatory and remodeling responses in a number of tissues. The specific KCa3.1 blocker 5-[(2-chlorophenyl) (diphenyl)methyl]-1H-pyrazole (TRAM-34) attenuates BSM cell proliferation, and both mast cell and fibrocyte recruitment in vitro. We aimed to examine the effects of KCa3.1 blockade on BSM remodeling, airway inflammation, and BHR in a murine model of chronic asthma. BALB/c mice were sensitized with intraperitoneal ovalbumin (OVA) on Days 0 and 14, and then challenged with intranasal OVA during Days 14-75. OVAsensitized/challenged mice received TRAM-34 (120 mg/kg/day, subcutaneous) from Days -7 to 75 (combined treatment), Days -7 to 20 (preventive treatment), or Days 21 to 75 (curative treatment). Untreated mice received daily injections of vehicle (n = 8 per group). Bronchial remodeling was assessed by histological and immunohistochemical analyses. Inflammation was evaluated using bronchoalveolar lavage and flow cytometry. We also determined BHR in both conscious and anesthetized mice via plethysmography. We demonstrated that curative treatment with TRAM-34 abolishes BSM remodeling and subbasement collagen deposition, and attenuates airway eosinophilia. Although curative treatment alone did not significantly reduce BHR, the combined treatment attenuated nonspecific BHR to methacholine. This study indicates that KCa3.1 blockade could provide a new therapeutic strategy in asthma.",
keywords = "Asthma, Ion channel, K3.1, Remodeling, Smooth muscle",
author = "Girodet, {Pierre Olivier} and Annaig Ozier and Gabrielle Carvalho and Olga Ilina and Olga Ousova and Gadeau, {Alain Pierre} and Hugues Begueret and Heike Wulff and Roger Marthan and Peter Bradding and Patrick Berger",
year = "2013",
month = "2",
doi = "10.1165/rcmb.2012-0103OC",
language = "English (US)",
volume = "48",
pages = "212--219",
journal = "American Journal of Respiratory Cell and Molecular Biology",
issn = "1044-1549",
publisher = "American Thoracic Society",
number = "2",

}

TY - JOUR

T1 - Ca2+-activated K+ channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model

AU - Girodet, Pierre Olivier

AU - Ozier, Annaig

AU - Carvalho, Gabrielle

AU - Ilina, Olga

AU - Ousova, Olga

AU - Gadeau, Alain Pierre

AU - Begueret, Hugues

AU - Wulff, Heike

AU - Marthan, Roger

AU - Bradding, Peter

AU - Berger, Patrick

PY - 2013/2

Y1 - 2013/2

N2 - Key features of asthma include bronchial hyperresponsiveness (BHR), eosinophilic airway inflammation, and bronchial remodeling, characterized by subepithelial collagen deposition, airway fibrosis, and increased bronchial smooth muscle (BSM) mass. The calcium-activated K+ channel K Ca3.1 is expressed by many cells implicated in the pathogenesis of asthma, and is involved in both inflammatory and remodeling responses in a number of tissues. The specific KCa3.1 blocker 5-[(2-chlorophenyl) (diphenyl)methyl]-1H-pyrazole (TRAM-34) attenuates BSM cell proliferation, and both mast cell and fibrocyte recruitment in vitro. We aimed to examine the effects of KCa3.1 blockade on BSM remodeling, airway inflammation, and BHR in a murine model of chronic asthma. BALB/c mice were sensitized with intraperitoneal ovalbumin (OVA) on Days 0 and 14, and then challenged with intranasal OVA during Days 14-75. OVAsensitized/challenged mice received TRAM-34 (120 mg/kg/day, subcutaneous) from Days -7 to 75 (combined treatment), Days -7 to 20 (preventive treatment), or Days 21 to 75 (curative treatment). Untreated mice received daily injections of vehicle (n = 8 per group). Bronchial remodeling was assessed by histological and immunohistochemical analyses. Inflammation was evaluated using bronchoalveolar lavage and flow cytometry. We also determined BHR in both conscious and anesthetized mice via plethysmography. We demonstrated that curative treatment with TRAM-34 abolishes BSM remodeling and subbasement collagen deposition, and attenuates airway eosinophilia. Although curative treatment alone did not significantly reduce BHR, the combined treatment attenuated nonspecific BHR to methacholine. This study indicates that KCa3.1 blockade could provide a new therapeutic strategy in asthma.

AB - Key features of asthma include bronchial hyperresponsiveness (BHR), eosinophilic airway inflammation, and bronchial remodeling, characterized by subepithelial collagen deposition, airway fibrosis, and increased bronchial smooth muscle (BSM) mass. The calcium-activated K+ channel K Ca3.1 is expressed by many cells implicated in the pathogenesis of asthma, and is involved in both inflammatory and remodeling responses in a number of tissues. The specific KCa3.1 blocker 5-[(2-chlorophenyl) (diphenyl)methyl]-1H-pyrazole (TRAM-34) attenuates BSM cell proliferation, and both mast cell and fibrocyte recruitment in vitro. We aimed to examine the effects of KCa3.1 blockade on BSM remodeling, airway inflammation, and BHR in a murine model of chronic asthma. BALB/c mice were sensitized with intraperitoneal ovalbumin (OVA) on Days 0 and 14, and then challenged with intranasal OVA during Days 14-75. OVAsensitized/challenged mice received TRAM-34 (120 mg/kg/day, subcutaneous) from Days -7 to 75 (combined treatment), Days -7 to 20 (preventive treatment), or Days 21 to 75 (curative treatment). Untreated mice received daily injections of vehicle (n = 8 per group). Bronchial remodeling was assessed by histological and immunohistochemical analyses. Inflammation was evaluated using bronchoalveolar lavage and flow cytometry. We also determined BHR in both conscious and anesthetized mice via plethysmography. We demonstrated that curative treatment with TRAM-34 abolishes BSM remodeling and subbasement collagen deposition, and attenuates airway eosinophilia. Although curative treatment alone did not significantly reduce BHR, the combined treatment attenuated nonspecific BHR to methacholine. This study indicates that KCa3.1 blockade could provide a new therapeutic strategy in asthma.

KW - Asthma

KW - Ion channel

KW - K3.1

KW - Remodeling

KW - Smooth muscle

UR - http://www.scopus.com/inward/record.url?scp=84873357122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873357122&partnerID=8YFLogxK

U2 - 10.1165/rcmb.2012-0103OC

DO - 10.1165/rcmb.2012-0103OC

M3 - Article

C2 - 23204391

AN - SCOPUS:84873357122

VL - 48

SP - 212

EP - 219

JO - American Journal of Respiratory Cell and Molecular Biology

JF - American Journal of Respiratory Cell and Molecular Biology

SN - 1044-1549

IS - 2

ER -